Drug Profile
Research programme: interleukin-2 monoclonal antibodies - Xoma
Alternative Names: anti-IL-2 antibodies - Xoma; IL-2/mab complexes - Xoma; mAb19 + IL-2Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator XOMA
- Class Antineoplastics; Interleukins; Monoclonal antibodies
- Mechanism of Action Interleukin 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 31 Dec 2022 XOMA Corporation has patent protection for 'Interleukin-2 Antibodies and Uses Thereof' in USA and Europe
- 28 Dec 2020 No development reported - Preclinical for Cancer in USA (Parenteral)
- 09 Mar 2020 XOMA Corporation enters into a license agreement with Zydus cadila to develop and commercialise interleukin-2 monoclonal antibodies in India, Brazil, Mexico